Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1992 Mar;33(3):281–288. doi: 10.1111/j.1365-2125.1992.tb04036.x

The effects of a selective 5-HT2 receptor antagonist (ICI 170,809) on platelet aggregation and pupillary responses in healthy volunteers.

D S Millson 1, C L Jessup 1, A Swaisland 1, S Haworth 1, A Rushton 1, J D Harry 1
PMCID: PMC1381276  PMID: 1576048

Abstract

1. ICI 170,809 (2-(2-dimethylamino-2-methylpropylthio)-3-phenylquinoline hydrochloride) is a potent 5-hydroxytryptamine (5-HT) type 2 postsynaptic receptor antagonist. 2. Effects of ICI 170,809 as single oral doses (3, 7, 15 and 30 mg) or placebo were studied on the duration of antagonism for the ex vivo platelet aggregatory response to 5-HT and to the pupillary light constrictor response in eight healthy male volunteers. 3. Pupillary dark adapted responses to a 0.5 s light stimulus were measured using a portable infrared pupillometer, for up to 24 h after dosing. 4. The in vitro platelet 5-HT aggregation response was reduced by ICI 170,809, with depression of the dose-response curve to 5-HT at all concentrations of 5-HT and with no evidence for a parallel shift. 5. The ex vivo platelet 5-HT response demonstrated a dose related significant (P less than 0.02) decrease in aggregation reaching a maximum at 2 h after dosing with the effect persisting for at least 8 h after dosing with the 7 and 15 mg doses. 6. Resting pupil diameter (RPD), and light induced pupillary responses in the dark adapted pupil, showed a significant (P less than 0.01) dose related reduction with significant (P less than 0.05) effects still present with the 15 and 30 mg doses at 8 h after dosing. 7. We conclude that, changes in both ex vivo platelet aggregation to 5-HT and dark adapted pupil size, are significantly correlated (P less than 0.0001) with log plasma concentrations (ng ml-1) of ICI 170,809, enabling the assessment of 5-HT2-receptor antagonism in man.

Full text

PDF
281

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bevan J., Heptinstall S. Effects of combinations of 5-hydroxytryptamine receptor antagonists on 5-HT-induced human platelet aggregation. Naunyn Schmiedebergs Arch Pharmacol. 1986 Dec;334(4):341–345. doi: 10.1007/BF00569367. [DOI] [PubMed] [Google Scholar]
  2. Biegon A., Weizman A., Karp L., Ram A., Tiano S., Wolff M. Serotonin 5-HT2 receptor binding on blood platelets--a peripheral marker for depression? Life Sci. 1987 Nov 30;41(22):2485–2492. doi: 10.1016/0024-3205(87)90675-8. [DOI] [PubMed] [Google Scholar]
  3. Blackburn T. P., Cox B., Thornber C. W., Pearce R. J. Pharmacological studies in vivo with ICI 169,369, a chemically novel 5-HT2/5-HT1C receptor antagonist. Eur J Pharmacol. 1990 May 16;180(2-3):229–237. doi: 10.1016/0014-2999(90)90306-q. [DOI] [PubMed] [Google Scholar]
  4. Blackburn T. P., Thornber C. W., Pearce R. J., Cox B. In vitro studies with ICI 169,369, a chemically novel 5-HT antagonist. Eur J Pharmacol. 1988 Jun 10;150(3):247–256. doi: 10.1016/0014-2999(88)90005-2. [DOI] [PubMed] [Google Scholar]
  5. Blauw G. J., van Brummelen P., Chang P. C., Vermeij P., van Zwieten P. A. Regional vascular effects of serotonin and ketanserin in young, healthy subjects. Hypertension. 1988 Mar;11(3):256–263. doi: 10.1161/01.hyp.11.3.256. [DOI] [PubMed] [Google Scholar]
  6. Conn P. J., Sanders-Bush E. Regulation of serotonin-stimulated phosphoinositide hydrolysis: relation to the serotonin 5-HT-2 binding site. J Neurosci. 1986 Dec;6(12):3669–3675. doi: 10.1523/JNEUROSCI.06-12-03669.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cutcliffe N., Osborne N. N. Serotonergic and cholinergic stimulation of inositol phosphate formation in the rabbit retina. Evidence for the presence of serotonin and muscarinic receptors. Brain Res. 1987 Sep 22;421(1-2):95–104. doi: 10.1016/0006-8993(87)91279-0. [DOI] [PubMed] [Google Scholar]
  8. Davies P. T., Steiner T. J. Serotonin S2 receptors and migraine: a study with the selective antagonist ICI 169,369. Headache. 1990 May;30(6):340–343. doi: 10.1111/j.1526-4610.1990.hed3006340.x. [DOI] [PubMed] [Google Scholar]
  9. De Clerck F., Van Nueten J. M. Platelet-mediated vascular contractions: inhibition of the serotonergic component by ketanserin. Thromb Res. 1982 Sep 15;27(6):713–727. doi: 10.1016/0049-3848(82)90009-3. [DOI] [PubMed] [Google Scholar]
  10. Frenken M., Kaumann A. J. Dimethylation of the activator ICI 169,369 results in a high-affinity partial deactivator, ICI 170,809, of the arterial 5-hydroxytryptamine2 receptor system. J Pharmacol Exp Ther. 1989 Aug;250(2):707–713. [PubMed] [Google Scholar]
  11. GADDUM J. H., PICARELLI Z. P. Two kinds of tryptamine receptor. Br J Pharmacol Chemother. 1957 Sep;12(3):323–328. doi: 10.1111/j.1476-5381.1957.tb00142.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Goldstein J. M., Litwin L. C., Sutton E. B., Malick J. B. Effects of ICI 169,369, a selective serotonin2 antagonist, in electrophysiological tests predictive of antipsychotic activity. J Pharmacol Exp Ther. 1989 Jun;249(3):673–680. [PubMed] [Google Scholar]
  13. Jansen I., Blackburn T., Eriksen K., Edvinsson L. 5-hydroxytryptamine antagonistic effects of ICI 169,369, ICI 170,809 and methysergide in human temporal and cerebral arteries. Pharmacol Toxicol. 1991 Jan;68(1):8–13. doi: 10.1111/j.1600-0773.1991.tb01200.x. [DOI] [PubMed] [Google Scholar]
  14. Kramer R., Rubicek M., Turner P. The role of norfenfluramine in fenfluramine-induced mydriasis. J Pharm Pharmacol. 1973 Jul;25(7):575–576. doi: 10.1111/j.2042-7158.1973.tb09161.x. [DOI] [PubMed] [Google Scholar]
  15. Marasini B., Biondi M. L., Mollica R. Effect of chronic ketanserin treatment on serotonin-induced platelet aggregation in patients with Raynaud's phenomenon. Eur J Clin Pharmacol. 1990;39(3):289–290. doi: 10.1007/BF00315113. [DOI] [PubMed] [Google Scholar]
  16. Millson D. S., Haworth S. J., Rushton A., Wilkinson D., Hobson S., Harry J. The effects of a 5-HT2 receptor antagonist (ICI 169,369) on changes in waking EEG, pupillary responses and state of arousal in human volunteers. Br J Clin Pharmacol. 1991 Oct;32(4):447–454. doi: 10.1111/j.1365-2125.1991.tb03929.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Moro F., Scapagnini U., Scaletta S., Drago F. Serotonin nerve endings and regulation of pupillary diameter. Ann Ophthalmol. 1981 Apr;13(4):487–490. [PubMed] [Google Scholar]
  18. Pazos A., Probst A., Palacios J. M. Serotonin receptors in the human brain--IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience. 1987 Apr;21(1):123–139. doi: 10.1016/0306-4522(87)90327-7. [DOI] [PubMed] [Google Scholar]
  19. Peroutka S. J., Lebovitz R. M., Snyder S. H. Two distinct central serotonin receptors with different physiological functions. Science. 1981 May 15;212(4496):827–829. doi: 10.1126/science.7221567. [DOI] [PubMed] [Google Scholar]
  20. Pritchett D. B., Bach A. W., Wozny M., Taleb O., Dal Toso R., Shih J. C., Seeburg P. H. Structure and functional expression of cloned rat serotonin 5HT-2 receptor. EMBO J. 1988 Dec 20;7(13):4135–4140. doi: 10.1002/j.1460-2075.1988.tb03308.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Tobin A. B., Unger W., Osborne N. N. Evidence for the presence of serotonergic nerves and receptors in the iris-ciliary body complex of the rabbit. J Neurosci. 1988 Oct;8(10):3713–3721. doi: 10.1523/JNEUROSCI.08-10-03713.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Uusitalo H., Lehtosalo J., Laakso J., Härkonen M., Palkama A. Immunohistochemical and biochemical evidence for 5-hydroxytryptamine containing nerves in the anterior part of the eye. Exp Eye Res. 1982 Dec;35(6):671–675. doi: 10.1016/s0014-4835(82)80079-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES